

The PRIVAK status was created by a Royal Decree of 18 April 1997 and is part of a wider raft of measures taken by the Belgian government to boost investment in venture capital. PRIVAKs were initially required to apply for a listing on the Belgian stock exchange, but in May 2003, the regulator granted them the option to remain private, which means that their shareholder structures can be reserved exclusively for private investors. The PRIVAK is obliged to pay out at least 80% of the profits that stem from the realized capital gains of its accounting year.

ONLY TWO BELGIAN PRIVAKS

Quest for Growth and KBC Biotech are currently the only two public PRIVAKs in Belgium. It is unsure that other public PRIVAKs are currently being set up.



The first company to be awarded the PRIVAK status was Quest for Growth, which received the status in 1998. Quest for Growth is focused on investing money in technology and high growth companies and has a clear-cut policy for investments in listed stocks.



The KBC Private Equity Fund Biotech (KBC Biotech) was the second PRIVAK to be launched and was approved in 2001. KBC Biotech has invested exclusively in biotechnology companies. Its investments in listed stakes are mainly done on the Nasdaq stock exchange.

OVERSEEN BY THE CBFA

Companies with PRIVAK status are monitored by the CBFA, the Belgian market regulator. The name PRIVAK is derived from 'Private Equity' and 'Bevak' (closed-end investment company). In essence, a PRIVAK is a Belgian closed-end investment company that provides a framework for private investors to invest directly in admissible financial instruments issued by unlisted companies and growth companies.

INVESTMENT CRITERIA

PRIVAKs are subject to very strict investment criteria and are subject to some constraints concerning dividend payments.

1. At least 50% of the portfolio must be invested in equity.
2. At least 70% of the portfolio must be invested in so-called qualified investments, which are investments in non-quoted companies, companies that are quoted in a growth market or investments in private equity funds with a similar investment profile to the PRIVAK.
3. Investments in companies quoted on a growth market must be limited to 50% of the above-mentioned qualified investments.
4. PRIVAKs may invest no more than 20% of total assets in a single company and must restrict the investments per company per year to a maximum of € 6.2m.

FISCAL BENEFITS

PRIVAKs are granted substantial tax benefits, over and above the exemption from capital gains tax normally granted to Belgian investment vehicles. A PRIVAK's dividends are exempt from withholding tax if at least 80% of the profits stem from realized capital gains and if the company complies with all of the investment criteria. The part of the dividend resulting from capital gains will be exempt from withholding tax, while the remaining part of the dividend will be subject to a withholding tax of 15%.

Description

Quest for Growth is a Belgian investment company focused on listed and unlisted growth companies with the objective of converting capital gains into tax-free income through the Privak-structure.



Investment cases

- Quest's investors benefit from Belgium's Privak statute, thanks to which the gross dividend is net of taxes
- Quest has a dynamically managed portfolio of listed stocks, leaving it vulnerable to the market's momentum
- Quest's unlisted investments have been subject to writedowns against a background of a frozen M&A market
- Our rating is entirely based on valuation grounds, as the stock is trading at relatively high discount levels



Shareholder structure

	# shs	% shs	value (€m)
Dexia Bank	1,393,813	11.82%	5.99
KBC Asset Mgt	574,357	4.87%	2.47
Laxey Partners	1,413,780	11.99%	6.08
Free float	8,407,305	71.31%	36.15

Dividend data



Volume and performance data



Analyst opinion

Stock price: € 4.35
 Target price: € 5.50
 Potential: 20.91%
 Rating: BUY

Company specifics

Market cap: € 51m
 Currency: EUR
 Avg. daily value: € 0.02m
 Avg. 3M volume: 6,604
 % chg 1M: 3.61%
 % chg 1Y: 2.87%
 52-week hi/lo: 4.95 / 3.6
 BB-code: QFG BB
 Reuters-code: QUFG.BR
 Web: www.questforgrowth.com

Corporate calendar

02-Jul-2010 NAV update (A)
 22-Jul-2010 Results 1H (A)
 23-Jul-2010 Analyst Meeting (A)
 06-Aug-2010 NAV update (A)
 03-Sep-2010 NAV update (A)
 01-Oct-2010 NAV update (A)

News flow

08-06-2010: CoreOptics deal boosts NAV, Anteryon joins ranks

NAV at end-May declined to € 7.48 per share, versus € 7.56 at end-April (-1.1% m/m, +3.2% YTD). The stock mimicked the movement and declined to € 4.25 (-5.6% m/m, -8.6% YTD), due to which the discount increased even further to 43.2% (end-April; 40.48%). Quest made quite a number of changes to its listed portfolio, mainly upping stakes in existing portfolio companies: Unit 4 Agresso, TKH Group, Teva Pharma, Arcadis, Faiveley, SMA Solar and Centrotec. Quest lowered positions in INIT and added new investments to the ranks as well: Econocom, Parrot ad Accel Group. It disposed entirely of its stake in Seloger.com (Tandberg was tendered to Cisco's takeover offer). Combined, the listed portfolio totals € 52.4m and accounts for 59.3% of NAV. Listed assets break down in Software & Services (14.3%), Technology & Hardware (6.9%), Pharma & Biotech (5.9%), Healthcare Equipment (2.7%), Electrical & Engineering (16.4%) and Materials & Others (6.9%). Quoted/unquoted assets (i.e. Movetis) account for 6.3% of NAV. The value of the direct Private Equity stakes wasn't subject to adjustments. Our SOTP model no longer lists the CoreOptics stake (as this is in the process of being sold), but includes Dutch micro-optics firm Anteryon, in which Quest yesterday invested € 1m alongside Qualcomm. Anteryon designs and produces micro-optics and refractive-optics, enabling wafer-based production and integration of optics for miniature camera and laser projection modules. It was spun out of electronics firm Philips in 2006. The fresh capital will be used on Anteryon's WaferOptics optical module production technology and the company's Asia production facility expansion. The valuation of the 3rd Party funds remained level with end-April reading as well, while Quest answered a € 0.12m capital call from Capricorn Cleantech Fund. The direct and indirect PE portfolios are valued at a respective € 16.1m and € 8.4m. Combined, PE stakes account for € 24.5m, or 27.8% of adjusted equity. We estimate net cash at € 9.5m (10.7% of NAV), which includes the valuation of options and other items on the balance sheet. We currently estimate adjusted equity value p.s. at € 7.50. We note that despite a broad number of past writedowns in the PE portfolio in the past and the fact that it has few options to create value via exits (IPO or trade sale), the stock's valuation is very undemanding: Quest's NAV performance relative to its stock price and its benchmark indices has held up quite well; the discount currently hovers a tad below 44%. The upside potential from current trading levels amounts to 28%.

28-05-2010: €2.5m CoreOptics gain increases stock's appeal

Quest for Growth sold its stake in CoreOptics to Nasdaq-listed Cisco Systems Inc, the worldwide leader in networking for the Internet. QfG has invested in CoreOptics since 2006 and participated in various financing rounds. The sale is expected to have a € 0.21 per share positive impact of approximately € 2.5m on last published NAV. Clearly, we regard the sale as a very positive item for Quest; an array of writedowns on the carrying value of the unlisted stakes (in 2009 and 2010) put question marks behind Quest's ability in creating value out of the unlisted portfolio. The monetization of CoreOptics thus reduces the "impairment risk". After the transaction, the unlisted portfolio accounts for 25.4%, which includes 3rd Party Funds (9.1%) and Clear2Pay (5.9%). The balance (€ 10.4m) consists almost entirely of Pharma & Biotech investments, with the biggest ones being Kiadis (2.2%), Sphere Medical (1.9%), Syntaxin (1.9%) and TCLand (1.7%). Despite disposing of scant financial details and bearing in mind that the valuation of these assets always depends on progress in bringing the pipeline to fruition, we believe the downside risk on the unlisted portfolio to be low. We estimate adjusted equity value per share at € 7.72. We remind that we increased our TP to € 5.5 a couple of weeks ago, based on the fact that the undervaluation in terms of discount combined with we believed to be a stable valuation of the unlisted portfolio offered an interesting entry point for investors. We stick to this view: At a 46% discount, Quest is cheap.

06-05-2010: TP and rating increase following April NAV update

NAV at end-April increased to € 7.56 per share, versus € 7.42 at end-March (+1.9% m/m, +4.3% YTD). The stock increased a tad to € 4.50 (+2.3% m/m, -3.2% YTD), due to which the discount remained more or less level with the end-March reading at 40.48%. Quest made some changes to its listed portfolio, upping stakes in Unit 4 Agresso, Roche Holdings, Imtech, Pfeiffer and Centrotec and lowering positions in Wirecard, Séloger, TKH group, Andritz, Arcadis and Vestas Wind Systems.. Quest didn't add new investments to the ranks, but disposed entirely of its Tandberg stake (which was subject to a takeover offer by Cisco). Combined, the listed portfolio totals € 56.5m and accounts for 61.5% of NAV. Listed assets break down in Software & Services (14.7%), Technology & Hardware (10.2%), Pharma & Biotech (4.6%), Healthcare Equipment (2.8%), Electrical & Engineering (16.1%) and Materials (5.6%). Quoted/unquoted assets (i.e. Movetis) account for 7.4% of NAV. The value of the direct Private Equity stakes wasn't subject to some adjustments as well. Quest halved the carrying value of Active Circle (from € 0.8m to € 0.4m) and converted the £ 0.28m Sphere Medical loan note into equity (this was already confirmed on the 1Q10 analyst meeting). The valuation of most of the 3rd Party funds was adjusted to reflect YE09 standing: valuation in general remained steady with previously reported levels. The direct and indirect PE portfolios are valued at a respective € 16.4m and € 8.3m. Combined, PE stakes account for € 24.7m, or 26.75% of adjusted equity. We currently estimate net cash at € 9.1m (9.9% of NAV), which includes the valuation of options and other items on the balance sheet. The official NAV figure still hovers south of our NAV estimate, due to a lock-up discount to the Movetis stake that shaves off around € 0.7 p.s. of the official NAV estimate. We are disappointed about the negative valuation adjustment at the level of Active Circle investment, but in general continue to believe that the underlying valuation of PE portfolio is stable. We estimate adjusted equity value per share at € 7.82. We note that despite a broad number of past writedowns in the Private Equity portfolio and the fact that it has few options to create value via exits (IPO or trade sale), valuations are still undemanding: Quest's NAV performance relative to its stock price and its benchmark indices has held up quite well; the discount currently hovers a tad below 44%. We therefore decided to increase our TP from € 5.25 to € 5.5, which reduces the implied discount versus NAV to 30%. The upside potential from current trading levels amounts to 25%, which prompted us to increase our rating from Accumulate to Buy.

23-04-2010: 1Q10 marks 4th consecutive quarterly profit

Quest in 1Q10 booked a € 2.08m profit (€ 0.18 p.s.), marking the 4th consecutive quarterly period that was written in black. The profit compares with a 1Q09 loss of € 2.07m (€ 0.18 p.s.) and FY09 profit of € 18.07m (€ 1.53 p.s.). Quest's monthly NAV updates had already unveiled that equity p.s. at end-1Q10 climbed to € 7.42 p.s., versus € 7.25 at end-FY09 (+2.3% ytd), while the stock decreased to € 4.40 (+5.4% ytd). As a result of the surprisingly negative stock price evolution, the discount narrowed to 40.7% (versus 35.9% at end-FY09). The 2.3% YTD rise of NAV compares with a 12.9% rise of the benchmark Nasdaq index (triggered by the rise of the USD vs. the EUR) and a 6.7% increase of the New Market 50 index. Overall, the first quarter brought little excitement for Quest for Growth. In terms of profitability the listed portfolio (again) accounts for almost all of the result, as the small-cap and speciality investor continued to profit from a sharp increase of specialty stocks (that lagged up until YE09). Earnings contribution from the privately-held portfolio amounted to € 0.2m, but the portfolio's underlying valuation has certainly stabilised; the need to impair valuations has evaporated and peer group valuations have risen on the back of higher economic growth expectations. Quest has also witnessed an improvement in the overall quality of new investment proposals for PE investments, which – coupled with more realistic valuation expectations – could indicate more investment activity further down the road. During 1Q10, Quest's AGM approved the proposed agreement between the company and Quest Management NV. The fee decreased from € 1.9m (€ 0.16 p.s.) to a fixed annual level of € 1.5bn (€ 0.13 p.s.). The agreement kicked in on 1 April 2010 and runs over 12 months. The Global Cost Ratio (all costs carried by QfG versus NAV) will be kept below 3.5%. Going forward, Quest believes that the economic recovery will persist, even in Europe, but also that the period of bargains on the stock markets, which have taken a head start on future growth, seems to be mostly over. The 1Q10

Please press [here](#) to request a full historical news flow overview of the company

Sum-of-the-parts model


Description	Sector/market	BB	Shares held	Recent change	Last price	Crcncy	% of NAV	Valuation (€)	
Quoted companies							14.31%	12.65	
Software & Services									
ECONOCOM	Euronext Brussels	ECONB BB	68,375	68,375	10.7	€	0.82%	0.73	
INIT	Deutsche Börse	IXX GY	95,000	-5,000	13.5	€	1.45%	1.28	
NEMETSCHEK	Deutsche Börse	NEM GR	135,000	0	22.7	€	3.47%	3.07	
TRANSICS	Euronext Brussels	TRAN BB	250,000	0	5.0	€	1.41%	1.24	
UNIT 4 AGRESSO	Euronext Amsterdam	UNIT4 NA	195,330	5,000	18.2	€	4.01%	3.55	
VIZRT	Deutsche Börse	VIZ GR	326,191	0	2.4	€	0.89%	0.78	
WIRECARD	Deutsche Börse	WDI GR	250,000	0	8.0	€	2.26%	2.00	
Technology Hardware									
EVS BROADCAST	Euronext Brussels	EVS BB	55,000	0	34.7	€	2.16%	1.91	
LEM HOLDING	Zwitzerland	LEHN SW	8,500	-1,500	332.5	CHF	2.30%	2.03	
PARROT	Euronext Paris	PARRO FP	30,000	30,000	13.2	€	0.45%	0.39	
TKH GROUP	Euronext Amsterdam	TWEKA NA	113,610	3,550	15.3	€	1.96%	1.74	
Pharma & Biotech							12.12%	10.72	
ABLYNX	Euronext Brussels	ABLX BB	115,000	0	7.7	€	1.00%	0.88	
MOVETIS°	Pharma & Biotech	MOVE BB	523,601	0	10.7	€	6.31%	5.58	
ROCHE HOLDINGS	SWX Swiss Exchange	ROG VX	20,000	0	160.0	CHF	2.60%	2.30	
TEVA PHARMACEUTICAL	Nasdaq	TEVA US	45,000	20,000	52.1	USD	2.21%	1.96	
Health Care Equipment & Svs									
UNITED DRUG	Dublin	UGD ID	1,018,628	0	2.3	€	2.69%	2.38	
Electrical & Engineering							16.36%	14.47	
ANDRITZ	Vienna	ANDR AV	70,000	0	44.3	€	3.50%	3.10	
ARCADIS	Euronext Amsterdam	ARCAD NA	240,000	5,000	14.1	€	3.83%	3.39	
FAIVELEY	Euronext Paris	LEY FP	25,000	5,000	51.3	€	1.45%	1.28	
IMTECH	Euronext Brussels	IM NA	82,055	5,000	22.1	€	2.05%	1.81	
PFEIFFER VACUUM TECHNO	Deutsche Börse		45,000	0	56.7	€	2.88%	2.55	
SMA SOLAR	Deutsche Börse	S92 GY	15,000	1,000	80.8	€	1.37%	1.21	
VESTAS WIND SYSTEMS	Copenhagen	VWS DC	30,000	0	278.0	DKK	1.27%	1.12	
Materials							5.98%	5.29	
CENTROTEC	Deutsche Börse		110,000	10,000	12.8	€	1.59%	1.41	
GEBERIT	SWX Swiss Exchange	GEBN VX	12,000	0	173.2	€	1.69%	1.50	
UMICORE	Euronext Brussels	UMI BB	100,000	0	23.9	€	2.70%	2.39	
Other sectors							0.96%	0.85	
ACCELL GROUP	Euronext Amsterdam	ACCEL NA	25,000	25,000	34.0	€	0.96%	0.85	
Loan notes							2.19%	1.94	
Private Equity investments							27.77%	24.56	
ACTIVE CIRCLE	Software & Services		equity	0.40		€	0.45%	0.40	
ANTERYON	Semiconductors		equity	1.00		€	1.13%	1.00	
CLEAR2PAY	Software & Services		equity	5.36	0.21	€	6.06%	5.36	
IDEA	Pharma & Biotech		equity	0.52		€	0.58%	0.52	
KIADIS	Pharma & Biotech		equity	2.00		€	2.26%	2.00	
MAGWELL	Software & Services		equity	0.43		€	0.49%	0.43	
PROSONIX	Pharma & Biotech		equity	1.31		£	1.48%	1.31	
SPHERE MEDICAL HOLDING	Pharma & Biotech		equity	1.79		£	2.03%	1.79	
SYNTAXIN	Pharma & Biotech		equity	1.82		£	2.06%	1.82	
TCLAND	Pharma & Biotech		equity	1.50		€	1.70%	1.50	
THIRD PARTY INV FUNDS			Funds	8.43	8.05	€	9.53%	8.43	
Portfolio							89.26%	78.93	
Net cash (incl. others & options)							10.74%	9.50	
Adjusted equity value							100.00%	88.43	
Number of shares (outstanding)								11,789,255	
Treasury shares (for remuneration purposes, resale, collateral,...)								2.20%	259,305
Treasury shares (available for cancellation)								0.00%	0
Number of shares (for per share)								11,789,255	
Quest for Growth last price								4.30	
Adjusted equity value p.s.								7.50	
Current discount								42.68%	
Target prices									
Target equity value								88.43	
Target equity value p.s.								7.50	
Discount to target equity value								42.68%	

KBCS has a BUY recommendation and a €5.5 target price.


The upside potential versus a stock price of € 4.3 equals 27.91%.

The implied discount of our € 5.5 target price vs. the target equity value is 26.68%.

Graphical portfolio breakdown



Historical NAV overview



Financial data

Income statement (€m)	04/05	2005	2006	2007	2008	2009
Sales & operating income	0.0	0.0	0.0	0.0	0.0	0.0
Result from operating activities	0.0	0.0	0.0	0.0	0.0	0.0
Result from financing activities	0.0	0.0	0.0	0.0	0.0	0.0
Result from extraordinary activities	0.0	0.0	0.0	0.0	0.0	0.0
Share of result of associates	0.0	0.0	0.0	0.0	0.0	0.0
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0
Discontinued activities	0.0	0.0	0.0	0.0	0.0	0.0
Minorities	0.0	0.0	0.0	0.0	0.0	0.0
Share of the group	4.6	7.3	21.5	0.6	-48.4	18.1
Adjusted net result	4.6	7.3	21.5	0.6	-48.4	18.1
Balance sheet (€m)	04/05	2005	2006	2007	2008	2009
Intangible assets & goodwill	0.0	0.0	0.0	0.0	0.0	0.0
Tangible assets	0.0	0.0	0.0	0.0	0.0	0.0
Participations acc. for under equity method	0.0	0.0	0.0	0.0	0.0	0.0
Other financial assets	0.0	0.0	0.0	0.0	0.0	0.0
Cash & cash equivalents	0.0	0.0	0.0	0.0	0.0	0.0
Other assets	0.0	0.0	0.0	0.0	0.0	0.0
TOTAL ASSETS	63.8	103.7	117.6	116.5	67.7	85.6
Equity attributable to holders of the parent	63.6	103.2	95.9	115.8	67.4	85.4
Minorities	0.0	0.0	0.0	0.0	0.0	0.0
Financial debt	0.0	0.0	0.0	0.0	0.0	0.0
Other liabilities	0.0	0.0	0.0	0.0	0.0	0.0
TOTAL LIABILITIES	63.8	110.6	117.6	116.5	67.7	85.6
net debt	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow statement (€m)	04/05	2005	2006	2007	2008	2009
Cash flow from operating activities	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow from investing activities	0.0	0.0	0.0	0.0	0.0	0.0
Dividends paid (consolidated)	0.0	0.0	0.0	0.0	0.0	0.0
Other cash flow from financing	0.0	0.0	0.0	0.0	0.0	0.0
Fx and changes to consolidation scope	0.0	0.0	0.0	0.0	0.0	0.0
Change in cash & equivalents	0.0	0.0	0.0	0.0	0.0	0.0
Per share data	04/05	2005	2006	2007	2008	2009
Year-end share price (€)	7.9	8.9	10.0	8.4	3.2	4.7
Year-end market cap (€ m)	42.8	84.0	94.6	99.0	37.1	54.8
Weighted average # shares	5,416,000	9,459,073	9,459,073	11,789,255	11,789,255	11,789,255
Weighted average # shares, diluted	5,416,000	9,459,073	9,459,073	11,789,255	11,789,255	11,789,255
Basic EPS (€)	0.85	0.77	2.28	0.05	-4.11	1.53
Diluted EPS (€)	0.85	0.77	2.28	0.05	-4.11	1.53
NBV (€)	11.7	10.9	10.1	9.8	5.7	7.2
Adjusted equity value (€)	11.7	10.9	12.4	9.9	9.9	7.3
Premium (-) / Discount to (vs. YE stock price)	32.71%	18.61%	19.48%	14.89%	14.89%	35.86%
Gross dividend	0.00	0.69	1.94	0.05	0.00	0.00
Gross dividend yield	0.00%	7.77%	19.40%	0.60%	0.00%	0.00%
Ratios	04/05	2005	2006	2007	2008	2009
Return on Equity (avg)	7.2%	7.0%	22.4%	0.5%	-71.9%	21.2%
Total return	9.7%	21.1%	34.5%	-15.5%	-62.5%	47.6%
Pay-out ratio (adjusted net result)	0.0%	99.9%	100.0%	96.7%	0.0%	0.0%
P/E	9.30	11.58	4.39	159.58	-0.77	3.03
P/NBV	0.67	0.81	0.99	0.86	0.55	0.64
Statutory data (€m)	04/05	2005	2006	2007	2008	2009
Result from operating activities	4.7	7.2	20.7	0.3	-48.6	16.9
Result from financing activities	-0.1	0.1	0.9	0.3	0.2	1.2
Result from extraordinary activities	0.0	0.0	0.0	0.0	0.0	0.0
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0
PROFIT/LOSS FOR THE PERIOD	4.6	7.3	21.5	0.6	-48.4	18.1
Dividends paid (statutory)	0.0	-7.2	-21.5	-0.6	0.0	0.0
Financial assets	63.0	103.2	117.3	116.1	67.1	85.1
Other assets	0.8	0.5	0.3	0.4	0.6	0.5
Capital and reserves	63.6	103.2	95.9	115.8	67.4	85.4
Provisions and deferred taxation	0.0	0.0	0.0	0.0	0.0	0.0
Liabilities	0.2	7.4	21.6	0.7	0.3	0.1
TOTAL ASSETS	63.8	110.6	117.6	116.5	67.7	85.6

Analyst certification: The analysts identified in this report each certify, with respect to the companies or securities that the individual analyses that (i) the views expressed in this publication reflect his or her personal views about the subject companies and securities, and (ii) he or she receives compensation that is based upon various factors, including his or her employer's total revenues, a portion of which are generated by his or her employer's investment banking activities, but not in exchange for expressing the specific recommendation(s) in this report.

This publication has been prepared by KBC Securities NV which is regulated by CBFA (Banking, Finance and Insurance Commission) or one of its European subsidiaries (together "KBC Securities"). This publication is provided for informational purposes only and is not intended to be an offer, or the solicitation of any offer, to buy or sell the securities referred to herein. No part of this publication may be reproduced in any manner without the prior written consent of KBC Securities.

The information herein has been obtained from, and any opinions herein are based upon, sources believed reliable, but neither KBC Securities nor its affiliates represent that it is accurate or complete, and it should not be relied upon as such. All opinions, forecasts, and estimates herein reflect our judgement on the date of this publication and are subject to change without notice.

From time to time, KBC Securities, its principals or employees may have a position in the securities referred to herein or hold options, warrants or rights with respect thereto or other securities of such issuers and may make a market or otherwise act as principal in transactions in any of these securities. Any such persons may have purchased securities referred to herein for their own account in advance of the release of this publication. KBC Securities and principals or employees of KBC Securities may from time to time provide investment banking or consulting services to, or serve as a director of a company being reported on herein.

This publication is provided solely for the information and use of professional investors who are expected to make their own investment decisions without undue reliance on this publication. Investors must make their own determination of the appropriateness of an investment in any securities referred to herein based on the merits and risks involved, their own investment strategy and their legal, fiscal and financial position. Past performance is no guarantee for future results. By virtue of this publication, none of KBC Securities or any of its employees shall be responsible for any investment decision.

KBC Securities has implemented certain in-house procedures known as Chinese walls that aim to prevent the inappropriate dissemination of inside information. E.g. a Chinese wall surrounds the corporate finance department within KBC Securities. Further measures have been taken with regard to the separation of certain activities that could lead to conflicts of interest with other activities within KBC Securities.

In the United States this publication is being distributed to U.S. Persons by KBC Financial Products USA, Inc., which accepts responsibility for its contents. Orders in any securities referred to herein by any U.S. investor should be placed with KBC Financial Products USA, Inc. and not with any of its foreign affiliates. KBC FP USA Inc. and/or its affiliates may own 1% or more of the subject company's common equity securities. KBCFP USA Inc. or its affiliates may have managed or co-managed a public offering of the subject company's securities in the past 12 months, or received compensation for investment banking services from the subject company in the past 12 months, or expect to receive or intend to seek compensation for investment banking services from the subject company in the next three months. Any U.S. recipient of this report that is not a bank or broker-dealer and that wishes to receive further information regarding, or to effect any transaction in, any security discussed in this report, should contact and place orders with KBC Financial Products USA Inc. This report is being distributed in the United States solely to investors that are (i) "major U.S. institutional investors" (within the meaning of SEC Rule 15a-6 and applicable interpretations relating thereto) that are also "qualified institutional buyers" (QIBs) within the meaning of SEC Rule 144A promulgated by the United States Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (the "Securities Act") or (ii) investors that are not "U.S. Persons" within the meaning of Regulation S under the Securities Act and applicable interpretations relating thereto. The offer or sale of certain securities in the United States may be made to QIBs in reliance on Rule 144A. Such securities may include those offered and sold outside the United States in transactions intended to be exempt from registration pursuant to Regulation S. This report does not constitute in any way an offer or a solicitation of interest in any securities to be offered or sold pursuant to Regulation S. Any such securities may not be offered or sold to U.S. Persons at this time and may be resold to U.S. Persons only if such securities are registered under the Securities Act of 1933, as amended, and applicable state securities laws, or pursuant to an exemption from registration. The products sold by KBC Financial Products USA, Inc or any affiliate thereof, including KBC Securities or KBC Financial Products UK Limited, are not insured by the FDIC, are not obligations of or guaranteed by KBC Bank NV or its affiliates, and are subject to investment risks, including possible loss of the entire amount invested.

This publication is for distribution in or from the United Kingdom only to persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 of the United Kingdom or any order made thereunder or to investment professionals as defined in Section 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and is not intended to be distributed or passed on, directly or indirectly, to any other class of persons.

This publication is for distribution in Canada only to pension funds, mutual funds, banks, asset managers and insurance companies.

The distribution of this publication in other jurisdictions may be restricted by law, and persons into whose possession this publication comes should inform themselves about, and observe, any such restrictions. In particular this publication may not be sent into or distributed, directly or indirectly, in Japan or to any resident thereof.